Asosiy kontentga oʻtish
Maqola

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Marie VétizouUniversity of Paris Sud XI, Kremlin-Bicêtre, FranceJonathan M. PittINSERM U1015, GRCC, Villejuif, FranceRomain DaillèreInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, FrancePatricia LepageInstitut National de la Recherche Agronomique (INRA), Micalis-UMR1319, 78360 Jouy-en-Josas, FranceNadine WaldschmittUniversity of Lille, CNRS, INSERM, Centre Hospitalier Régional Universitaire de Lille, Institut Pasteur de Lille, U1019, UMR 8204, Centre d'Infection et d'Immunité de Lille (CIIL), F-59000 Lille, FranceCaroline FlamentCenter of Clinical Investigations in Biotherapies of Cancer 1428, Villejuif, FranceSylvie RusakiewiczCenter of Clinical Investigations in Biotherapies of Cancer 1428, Villejuif, FranceBertrand RoutyBicêtre HospitalMaría P. RobertiInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, FranceConnie P.M. DuongINSERM U1015, GRCC, Villejuif, FranceVichnou Poirier-ColameINSERM U1015, GRCC, Villejuif, FranceAntoine RouxInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, FranceSonia BecharefInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, FranceSilvia C. FormentiDepartment of Radiation Oncology, New York University, New York, NY, USAEncouse B. GoldenDepartment of Radiation Oncology, New York University, New York, NY, USASascha CordingMicroenvironment and Immunity Unit, Institut Pasteur, Paris, FranceGérard EberlMicroenvironment and Immunity Unit, Institut Pasteur, Paris, FranceAndreas SchlitzerSingapore Immunology NetworkFlorent GinhouxSingapore Immunology NetworkSridhar ManiDepartment of Genetics and Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USATakahiro YamazakiCenter of Clinical Investigations in Biotherapies of Cancer 1428, Villejuif, FranceNicolas JacquelotInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, FranceDavid EnotLaboratoire d'études sur les monothéismesM BérardAnimalerie Centrale, Institut Pasteur, Paris, FranceJérôme NigouCentre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, FrancePaule OpolonInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, FranceAlexander EggermontDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, FrancePaul‐Louis WoertherService de microbiologie, GRCC, Villejuif, FranceÉlisabeth ChachatyService de microbiologie, GRCC, Villejuif, FranceNathalie ChaputInstitut Gustave RoussyCaroline RobertDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, FranceChristina MateusDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, FranceGuido KroemerMetabolomics Platform, GRCC, Villejuif, FranceDidier RaoultUnité des Rickettsies, Faculté de Médecine, Université de la Méditerranée, Marseille, FranceIvo G. BonecaINSERM, Equipe Avenir, Paris, FranceFranck CarbonnelGastroenterology Department, Hôpital Bicêtre, Assistance Publique—Hôpitaux de Paris, Paris, FranceMathias ChamaillardCenter for Infection and Immunity of LilleLaurence ZitvogelInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France
2015en
ABI

Annotatsiya

Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

4 ta iqtibos0 ta foydalanilgan manba